Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.

Jul 26, 2016, 08:50 ET from Chelmsford Park SA

NEW YORK, July 26, 2016 /PRNewswire/ --

The Healthcare sector presents some of the most profitable trades in the market, but challenges, such as ransom-ware risks, demand pressures, and cost issues, continue to persist. Today, presents these four companies for further assessment: Intrexon Corp. (NYSE: XON), Alkermes PLC (NASDAQ: ALKS), BioScrip Inc. (NASDAQ: BIOS), and Heartware International Inc. (NASDAQ: HTWR). Learn more about these stocks by accessing their freenotes at:


At the close on Monday, Germantown, Maryland-based Intrexon Corp.'s stock rose 1.54%, ending the day at $24.38 with a total volume of 860,514 shares traded. Shares of the Company, which operates in the synthetic biology field in the U.S., are trading below their 50-day moving average by 7.10%. The stock has a Relative Strength Index (RSI) of 44.02.

On June 30th, 2016, Intrexon and ZIOPHARM Oncology, Inc. announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve alignment between both companies as ZIOPHARM broadens its pipeline and advances multiple therapeutic programs into the clinic. Some major terms of the amendments: operating profit rates payable to Intrexon from ZIOPHARM on products developed under its two existing collaborations will be reduced from 50% to 20%. This reduction will not apply to any royalties or other payments made with respect to the companies' existing collaboration with Merck Serono, the biopharmaceutical business of Merck KGaA; economics from any future sublicensing arrangements with potential third party collaborators will remain evenly split. Visit us today and access our complete notes on XON at:


Shares in Dublin, Ireland headquartered Alkermes PLC ended the day 0.64% higher at $50.12 and with a total volume of 653,038 shares traded. In the last month and the previous three months, the stock has gained 14.56% and 17.32%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 13.13% and 0.14%, respectively. Furthermore, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 67.56.

On July 21st, 2016, Alkermes announced that it will host a conference call at 8:30 a.m. EDT on July 28th, 2016, to discuss the company's Q2 2016 financial results. The complimentary notes on ALKS can be accessed at:


On Monday, shares in Denver, Colorado-based BioScrip Inc. finished 3.09% higher at $2.67. A total volume of 768,554 shares was traded. The stock has advanced 1.52% over the previous three months and 52.57% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 2.48% and 22.13%, respectively. Additionally, shares of BioScrip, which provides home infusion services in the U.S., have an RSI of 53.05.

On June 22nd, 2016, BioScrip announced that it has completed its previously announced underwritten public offering of 45,200,000 shares, including 5,200,000 shares of common stock issued upon full exercise of the underwriters' over-allotment option, at a public offering price of $2.00 per share. The Offering resulted in net proceeds of approximately $83.15 million. The Company intends to use the net proceeds from the offer to fund the cash portion of the previously announced proposed acquisition of substantially all the assets of HS Infusion Holdings, Inc. and pay fees and expenses in connection with the Transaction, to repay a portion of outstanding borrowings under its revolving credit facility and for general corporate purposes. Register for free on and access the latest notes on BIOS at:

Heartware Intl. 

Framingham, Massachusetts headquartered Heartware International Inc.'s shares recorded a trading volume of 166,349 shares at the end of yesterday's session and closed the day at $57.82, gaining 0.10%. The stock has soared 74.42% in the last one month, 70.31% over the previous three months, and 14.72% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 42.54% and 48.02%, respectively. Additionally, shares of Heartware International have, which designs, develops, manufactures, and markets miniaturized implantable heart pumps or ventricular assist devices for the treatment of advanced heart failure in the U.S., Germany, and globally, have an RSI at 82.43.

On June 27th, 2016, Medtronic PLC announced that it will acquire HeartWare in a transaction valued at approximately $1.1 billion. Under the terms of the agreement, Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash. The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic`s second fiscal quarter ending Oct. 28th, 2016, subject to the satisfaction of customary closing conditions.

On July 13th, 2016, research firm Raymond James downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.Get free access to your notes on HTWR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA